Bolender v. Bio-Medical Applications of Virginia, Inc.

CourtDistrict Court, W.D. Virginia
DecidedJune 24, 2024
Docket7:23-cv-00245
StatusUnknown

This text of Bolender v. Bio-Medical Applications of Virginia, Inc. (Bolender v. Bio-Medical Applications of Virginia, Inc.) is published on Counsel Stack Legal Research, covering District Court, W.D. Virginia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Bolender v. Bio-Medical Applications of Virginia, Inc., (W.D. Va. 2024).

Opinion

IN THE UNITED STATES DISTRICT COURT coi □□□□ FOR THE WESTERN DISTRICT OF VIRGINIA LAURAA AUSTIN, CLERK ROANOKE DIVISION mF Sepurv LEM JOYCE BOLENDER, ) ) Plaintiff, ) Civil Action No. 7:23-cv-00245 } ) MEMORANDUM OPINION ) BIO-MEDICAL APPLICATIONS OF _ ) By: | Hon. Thomas T. Cullen VIRGINIA, INC. & FRESENIUS USA) United States District Judge MANUFACTURING, INC. d/b/a ) PRESENIUS MEDICAL CARE ) NORTH AMERICA, ) ) Defendants. )

Plaintiff Joyce Bolender brought suit against Defendants Bio-Medical Applications of Virginia, Inc. ““CBMA”) and Fresenius USA Manufacturing, Inc. d/b/a Fresenius Medical Care North America (“Fresenius Manufacturing” and, together with BMA, “Defendants”, alleging Defendants’ termination of her employment constituted age discrimination in violation of (1) the Age Discrimination in Employment Act of 1967 (“ADEA”) and (2) the Virginia Human Rights Act (“VHRA”). The matter is now before the court on Defendants’ motion for summary judgment. For the reasons discussed below, the court will grant the motion as to Bolender’s VHRA claim, but deny it in all other respects.

I. STATEMENT OF FACTS The following facts are either undisputed or presented in the light most favorable to Bolender, the nonmoving party.1 See Glynn v. EDO Corp., 710 F.3d 209, 213 (4th Cir. 2013)

(citing Bonds v. Leavitt, 629 F.3d 369, 380 (4th Cir. 2011)). A. Corporate Structure Because the parties dispute what entities were Bolender’s employers, this section summarizes aspects of Defendants’ corporate form that were pertinent to Bolender’s previous employment as a social worker at the Fresenius Kidney Care dialysis center in Salem, Virginia. Each Defendant is an indirect, wholly-owned subsidiary of Fresenius Medical Care AG

& Co. KGaA (ECF Nos. 9–10), which, through its worldwide affiliates and subsidiaries (collectively, “Fresenius”), runs dialysis clinics that treat patients with kidney disease. (Bost Decl. ¶¶ 3–5 [ECF No. 24-2]; Disciplinary Guideline at 1–2 [ECF No. 25-4].) Fresenius uses a number of different names for both its internal and external operations.

1 Defendants assert that Bolender did not object to or dispute their summary judgment brief’s “Statement of Undisputed Material Facts,” so the court must accept Defendants’ proffered facts as true. (Reply Br. at 3–4 [ECF No. 29].) That is incorrect. Bolender did not provide pointed objections to each of the 52 paragraphs in Defendants’ statement of facts—as may have been best practice—but she did “very much dispute[]” Defendants’ facts and set forth, in detail and with citations to the record, evidence that demonstrates genuine issues of material facts. (See Pl.’s Br. at 3–13 [ECF No. 25].) Unlike some other courts in the Fourth Circuit, this court’s local rules do not require a party to follow a specific format when disputing facts in a summary-judgment response brief. Compare W.D. Va. Local Civ. R. 56, with E.D. Va. Local Civ. R. 56 (requiring that a response brief list all material facts that are disputed). Additionally, although Bolender’s response does not identify the disputed evidence on a point-by-point basis, the court does not simply accept Defendants’ facts given that the record provided as part of both Defendants’ motion and Bolender’s response shows, on its face, genuine factual disputes on key items. See Fed. R. Civ. P. 56(e)(2) advisory committee’s note to 2010 amendments (“[T]he court may choose not to consider [a] fact as undisputed, particularly if the court knows of record materials that show grounds for genuine dispute.”). At bottom, the fact section in Bolender’s response brief did not meaningfully affect Defendants’ ability to address her response, as indicated by their thorough reply brief, or the court’s ability to resolve the instant motion. Cf. Dixon Lumber Co., Inc. v. Austinville Limestone Co. Inc., 256 F. Supp. 3d 658, 666–67 (W.D. Va. 2017). The court, therefore, does not treat Defendants’ statement of facts as undisputed, and instead considers the totality of the evidence submitted by both parties. Internally, policy documents refer to the company as, among other things, “Fresenius Medical Care North America,” “Fresenius Medical Care,” and “FME.” (See, e.g., Bost Decl. Exs. A–B; Disciplinary Guideline.) Some employee email signatures display “Fresenius Kidney

Care.” (See Bost Decl. Ex. E.) And some clinic supplies are labeled with “Fresenius USA Manufacturing.” (Bolender Dep. 52:4–6 [ECF No. 25-3].) Bolender’s W-2s similarly reflect multiple Fresenius entities. Her 2020 W-2 notes “Bio-Medical Applications of Virginia, Inc.” as her employer, but her 2021 and 2022 W-2s state that her employer was “Fresenius Management Services, Inc.” (ECF No. 24-5 at 41–43.) Externally, Fresenius is also known by several names. For example, the company

advertises to the public that its dialysis centers function as “part of Fresenius Medical Care North America (FMCNA) . . . [and] may be known as Fresenius Kidney Care or Fresenius Medical Care, as well as other names.” (ECF No. 25-6 at 2.) One of those other names, according to Bolender, is “Fresenius Renal Care.” (Bolender Dep. 49:7–8, 221:3–5.) Virginia’s State Corporation Commission (“SCC”) sets forth even more names associated with Fresenius. Of note, the SCC lists “Fresenius USA Manufacturing, Inc.” as a

legal entity registered to do business in Virginia. (ECF No. 25-7.) The SCC’s records further show that “Fresenius Medical Care North America” is one of Fresenius Manufacturing’s fictitious names but not a standalone entity. (Id.) “Fresenius Management Services, Inc.,” the employer listed on Bolender’s 2021 and 2022 W-2s, is not registered with the SCC as either a legal entity or fictitious name. (Id.; see also Bolender Dep. 238:17–240:1.) B. Bolender’s Employment and Termination Bolender worked at Fresenius from November 3, 2014, until October 24, 2022. (Foley Dep. 26:2–4 [ECF No. 25-1]; Foley Decl. ¶ 18 [ECF No. 24-4].) Megan Foley both recruited

Bolender to join the company and fired her eight years later. (Bolender Dep. 19:18–20:16; Foley Decl. ¶ 18.) Bolender was 81 years old when her employment was terminated. (Bolender Dep. 195:2–4.) As a social worker at Fresenius, Bolender “provid[ed] services, support, and education to patients and their famil[ies].” (Foley Decl. ¶ 7.) She also collaborated with multiple members of patients’ care teams (e.g., doctors, nurses, and dieticians) to treat Fresenius patients.

(Bolender Dep. 85:6–89:21.) Bolender’s responsibilities included assessing patients’ eligibility for kidney transplants and completing documentation for their files. (Foley Decl. ¶ 7.) One such document was the transplant assessment form. Bolender completed this form after her initial meeting with a patient and updated it quarterly to reflect the patient’s medical status and eligibility for a transplant. (Id. ¶¶ 8–9.) Before completing the quarterly update, Bolender was expected to confirm the patient’s status with the patient, one of the patient’s family members,

the transplant center, or a member of the care team. (Id. ¶ 8.) Bolender performed well as a social worker at Fresenius. She was never disciplined prior to her termination (Foley Dep. 50:20–51:5), and her performance evaluations reflected “many glowing comments,” along with certain areas of opportunity, “that show[ed] she [was] an asset to the team” (Foley Decl. at 28). Foley authored many of those plaudits as Bolender’s manager. Among myriad positive remarks in her 2019 annual review, for example, Foley said

that Bolender was generous, thoughtful, and built trust with patients. (Id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

McDonnell Douglas Corp. v. Green
411 U.S. 792 (Supreme Court, 1973)
Texas Department of Community Affairs v. Burdine
450 U.S. 248 (Supreme Court, 1981)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
O'CONNOR v. Consolidated Coin Caterers Corp.
517 U.S. 308 (Supreme Court, 1996)
Kolstad v. American Dental Assn.
527 U.S. 526 (Supreme Court, 1999)
Arbaugh v. Y & H Corp.
546 U.S. 500 (Supreme Court, 2006)
Gross v. FBL Financial Services, Inc.
557 U.S. 167 (Supreme Court, 2009)
Haywood v. Locke
387 F. App'x 355 (Fourth Circuit, 2010)
Bonds v. Leavitt
629 F.3d 369 (Fourth Circuit, 2011)
Snowden v. Checkpoint Check Cashing
290 F.3d 631 (Fourth Circuit, 2002)
Benjamin Reynolds v. American National Red Cross
701 F.3d 143 (Fourth Circuit, 2012)
Kimberly Laing v. Federal Express Corporation
703 F.3d 713 (Fourth Circuit, 2013)
Dennis Glynn v. EDO Corporation
710 F.3d 209 (Fourth Circuit, 2013)
Magnuson v. Peak Technical Services, Inc.
808 F. Supp. 500 (E.D. Virginia, 1992)

Cite This Page — Counsel Stack

Bluebook (online)
Bolender v. Bio-Medical Applications of Virginia, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/bolender-v-bio-medical-applications-of-virginia-inc-vawd-2024.